CSL Ltd. - ADR
CSLLY
Get informed when a big investor buys or sells
+ FollowMarket Cap$124.73B
Close$
Earnings Call Q4 2023
August 15, 2023 - AI Summary
CSL delivered strong full-year results, with revenue up 31% at constant currency and NPATA of $2.6 billion, up 20%.
The CSL Behring business saw strong growth in its Ig franchise, with sales up 21%. Plasma collections reached record levels, and the company dosed its first patients with HEMGENIX, a gene therapy for hemophilia B.
CSL Seqirus achieved strong sales growth, driven by FLUCELVAX, which was up 30%. The company also signed a licensing agreement with Arcturus Therapeutics for next-generation mRNA vaccine technology.
Exclusive for Stockcircle Pro members
Sign up
$22.64
32.1% downside
Current Fair Value
32.1% downsideOvervalued by 32.1% based on the discounted cash flow analysis.
Share Statistics
| Market cap | $124.73 Billion |
|---|---|
| Enterprise Value | $134.11 Billion |
| Dividend Yield | $0.71 (2.20%) |
| Earnings per Share | $-1.34 |
| Beta | 0.08 |
| Outstanding Shares | 1,915,647,916 |
Return
| Return on Equity | 3.04% |
|---|---|
| Return on Assets | 1.34% |
| Return on Invested Capital | 28.99% |
Valuation & Multiples
| P/E Ratio | -24.28 |
|---|---|
| PEG | 6.23 |
| Price to Sales | 2.08 |
| Price to Book Ratio | 4.17 |
| Enterprise Value to Revenue | 4.3 |
| Enterprise Value to EBIT | 16.35 |
| Enterprise Value to Net Income | 297 |
| Total Debt to Enterprise | 0.08 |
| Debt to Equity | 0.74 |
Revenue Sources
No data
Insider Trades
Last Earnings Call
Report Date
August 17, 2026
EPS Estimate
-
Average shareholder expectationRevenue Estimate
-
Average shareholder expectationInstitutional Put/Call Ratio
Market sentiment based on institutional option activity.
| Put/Call Ratio | 0.00000% |
|---|---|
| Total Calls | - |
| Total Puts | - |
Institutional Ownership
Holdings and activity of institutional investors.
| Ownership % | 0.00%▲ 0.00% |
|---|---|
| Total Invested | $600,885▼ 57.74% |
| Investors Holding | 6▼ 1.00% |
ESG Score
No data
About CSL Ltd.
29,000 employees
CEO: Paul Perreault CSL Limited is a global biopharmaceutical enterprise engaged in the discovery, development, production, marketing, and distribution of a wide array of medicinal and related products. Its operations span key markets including Australia, t...